Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Entasis Therapeutics (ETTX) stocks in Canada

Learn how to easily invest in Entasis Therapeutics stocks.

Entasis Therapeutics is a biotechnology business based in the US. Entasis Therapeutics stocks (ETTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.75 – a decrease of 9.38% over the previous week. Entasis Therapeutics employs 47 staff and has a market cap (total outstanding stock value) of $91.5 million.

How to buy shares in Entasis Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ETTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Entasis Therapeutics stock price (NASDAQ:ETTX)

Use our graph to track the performance of ETTX stocks over time.

Entasis Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$1.74
52-week range$1.76 - $3.88
50-day moving average $2.41
200-day moving average $2.54
Wall St. target price$7.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.14

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Entasis Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Entasis Therapeutics price performance over time

Historical closes compared with the close of $1.74 from 2022-01-21

1 week (2022-01-14) -9.38%
1 month (2021-12-23) -25.32%
3 months (2021-10-22) -34.09%
6 months (2021-07-23) -30.40%
1 year (2021-01-22) -49.86%
2 years (2020-01-24) -64.20%
3 years (2019-01-24) 5.34
5 years (2017-01-20) N/A

Entasis Therapeutics financials

Gross profit TTM $7 million
Return on assets TTM -54.17%
Return on equity TTM -88.57%
Profit margin 0%
Book value $0.87
Market capitalisation $91.5 million

TTM: trailing 12 months

Entasis Therapeutics share dividends

We're not expecting Entasis Therapeutics to pay a dividend over the next 12 months.

Entasis Therapeutics share price volatility

Over the last 12 months, Entasis Therapeutics's shares have ranged in value from as little as $1.76 up to $3.88. A popular way to gauge a stock's volatility is its "beta".

ETTX.US volatility(beta: 1.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entasis Therapeutics's is 1.5565. This would suggest that Entasis Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Entasis Therapeutics overview

Entasis Therapeutics Holdings Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co. , Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin.

Stocks similar to Entasis Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site